Cannabis
113
19
29
60
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
18 trials with published results (16%)
Research Maturity
60 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.9%
1 terminated out of 113 trials
98.4%
+11.8% vs benchmark
4%
4 trials in Phase 3/4
30%
18 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 60 completed trials
Clinical Trials (113)
Reducing Breathlessness With Dronabinol in COPD Patients
Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans
The Pharmacokinetics of a Hemp-Based Topical Product
Repeated Administration of Cannabis Varying in THC and CBD
Changes in Cognition and Psychiatric Disorder Symptoms During Cannabis Abstinence Using a Novel Discordant Twin Design
Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use
Repeated CBD Administration and Cannabis Outcomes
Improving Pain Disability With the Use of Oral Cannabinoids
Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance
Developing and Strengthening Cannabis Warnings: Warning Message Testing
Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4
Allergenic Risk Assessment of Hemp Seed
Nicotine and Cannabis Vape Labeling Experiment - Spring 2025
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3
Study on Regulated Cannabis Sales in Pharmacies
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
Cannabinoids, Learning, and Memory